Professor Sarah Blagden

Following medical training, Professor Blagden undertook subsequent specialist training in Medical Oncology at Addenbrooke’s Hospital in Cambridge and the Royal Marsden Hospital, London. She was awarded a CRUK Junior Clinician Scientist PhD fellowship to study fruit fly genetics at Cambridge University (2000-2004) and later held a Clinical Fellowship at the Institute of Cancer Research’s Drug Development Unit.

Professor Blagden was appointed as Senior Lecturer and Honorary Consultant at Imperial College in 2006 and established her laboratory studying the dysregulation of mRNA translation in cancer. In 2015 she moved to Oxford University as an Associate Professor of Experimental Oncology and was director of the Early Phase Clinical Trials Unit until 2021. She is Oxford's ECMC lead and runs a research group in the Old Road Campus Research Building. In July 2021, she took over leadership of the Oxford Clinical Trials Office (OCTO). Professor Blagden has been chief or principal investigator for a number of national and international clinical studies, is involved in cancer prevention and early diagnosis and her research focus is post-transcriptional gene regulation in ovarian cancer.